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Does short-term virologic failure translate to clinical events in
antiretroviral-naïve patients initiating antiretroviral therapy in
clinical practice?
Abstract
OBJECTIVE: To determine whether differences in short-term virologic failure among commonly used
antiretroviral therapy (ART) regimens translate to differences in clinical events in antiretroviral-naïve
patients initiating ART. DESIGN: Observational cohort study of patients initiating ART between
January 2000 and December 2005. SETTING: The Antiretroviral Therapy Cohort Collaboration
(ART-CC) is a collaboration of 15 HIV cohort studies from Canada, Europe, and the United States.
STUDY PARTICIPANTS: A total of 13 546 antiretroviral-naïve HIV-positive patients initiating ART
with efavirenz, nevirapine, lopinavir/ritonavir, nelfinavir, or abacavir as third drugs in combination with
a zidovudine and lamivudine nucleoside reverse transcriptase inhibitor backbone. MAIN OUTCOME
MEASURES: Short-term (24-week) virologic failure (>500 copies/ml) and clinical events within 2
years of ART initiation (incident AIDS-defining event, death, and a composite measure of these two
outcomes). RESULTS: Compared with efavirenz as initial third drug, short-term virologic failure was
more common with all other third drugs evaluated; nevirapine (adjusted odds ratio = 1.87, 95%
confidence interval (CI) = 1.58-2.22), lopinavir/ritonavir (1.32, 95% CI = 1.12-1.57), nelfinavir (3.20,
95% CI = 2.74-3.74), and abacavir (2.13, 95% CI = 1.82-2.50). However, the rate of clinical events
within 2 years of ART initiation appeared higher only with nevirapine (adjusted hazard ratio for
composite outcome measure 1.27, 95% CI = 1.04-1.56) and abacavir (1.22, 95% CI = 1.00-1.48).
CONCLUSION: Among antiretroviral-naïve patients initiating therapy, between-ART regimen,
differences in short-term virologic failure do not necessarily translate to differences in clinical
outcomes. Our results should be interpreted with caution because of the possibility of residual
confounding by indication.
CDoes short-term virologic failure translate to clinical
events in antiretroviral-naı¨ve patients initiating
antiretroviral therapy in clinical practice?
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ISSNObjective: To determine whether differences in short-term virologic failure among
commonly used antiretroviral therapy (ART) regimens translate to differences in clinical
events in antiretroviral-naı¨ve patients initiating ART.
Design: Observational cohort study of patients initiating ART between January 2000
and December 2005.
Setting: The Antiretroviral Therapy Cohort Collaboration (ART-CC) is a collaboration of
15 HIV cohort studies from Canada, Europe, and the United States.
Study participants: A total of 13 546 antiretroviral-naı¨ve HIV-positive patients initiat-
ing ART with efavirenz, nevirapine, lopinavir/ritonavir, nelfinavir, or abacavir as third
drugs in combination with a zidovudine and lamivudine nucleoside reverse transcrip-
tase inhibitor backbone.
Main outcome measures: Short-term (24-week) virologic failure (>500 copies/ml) and
clinical events within 2 years of ART initiation (incident AIDS-defining event, death, and
a composite measure of these two outcomes).
Results: Compared with efavirenz as initial third drug, short-term virologic failure was
more common with all other third drugs evaluated; nevirapine (adjusted odds
ratio¼1.87, 95% confidence interval (CI)¼1.58–2.22), lopinavir/ritonavir (1.32,
95% CI¼1.12–1.57), nelfinavir (3.20, 95% CI¼2.74–3.74), and abacavir (2.13,
95% CI¼1.82–2.50). However, the rate of clinical events within 2 years of ART
initiation appeared higher only with nevirapine (adjusted hazard ratio for composite
outcome measure 1.27, 95% CI¼1.04–1.56) and abacavir (1.22, 95% CI¼1.00–
1.48).
Conclusion: Among antiretroviral-naı¨ve patients initiating therapy, between-ART regi-
men, differences in short-term virologic failure do not necessarily translate to differ-
ences in clinical outcomes. Our results should be interpreted with caution because of
the possibility of residual confounding by indication.
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Combination antiretroviral therapy (ART) has resulted in
dramatic reductions in HIV-associated morbidity and
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2482 AIDS 2008, Vol 22 No 18typically underpowered to detect differences in these
clinical outcome measures.
Collaborations of observational cohort studies, a comp-
lementary study design to RCTs, may have the statistical
power to evaluate between-regimen differences in clinical
outcomes. However, results from such studies are likely to
be affected by confounding because of the nonrando-
mized selection of initial ART regimens in clinical
practice [4], often referred to as ‘confounding by
indication’ [5]. Statistical methods can adjust for
measured imbalances between treatment groups, but
unmeasured confounding can never be fully excluded [6].
Recognizing these limitations, observational HIV cohort
studies can play an important role in providing evidence
that is not available from RCTs [7,8].
Previous observational studies have evaluated between-
regimen differences in short-term virologic failure in
treatment-naı¨ve patients initiating ART in clinical
practice settings, often yielding findings consistent with
RCT results [9–21]. However, these studies have largely
been underpowered to evaluate between-regimen differ-
ences in clinical outcomes. Previously, the ART Cohort
Collaboration (ART-CC) evaluated between-regimen
differences in virologic and clinical outcomes in patients
initiating ART between 1996 and 2002 [22]. However,
several regimens evaluated in that study are no longer
widely used in clinical practice. Furthermore, ritonavir-
boosted (RTV) protease inhibitors (amprenavir, lopina-
vir, saquinavir, and indinavir) were evaluated together due
to the low number of such regimens in the database at the
time of the study. Heterogeneity of outcomes between
boosted protease inhibitor regimens may have affected
the overall findings for these regimens, which were found
to be inferior for both virologic and clinical outcomes,
relative to efavirenz (EFV). Here, we analyse the data
from an updated ART-CC database to evaluate between-
regimen differences in short-term virologic failure and
rates of clinical events among treatment-naı¨ve patients
initiating ART between 2000 and 2005; all analyses were
conducted at the level of the individual regimen. We
hypothesized that between-ART regimen differences in
short-term virologic failure would not fully predict the
effects on clinical endpoints.Methods
Cohorts
The Antiretroviral Therapy Cohort Collaboration (ART-
CC) is a collaboration of 15 HIV cohort studies from
Canada, Europe, and the United States that was
established in 2001. The collaboration has been described
in detail elsewhere [23–26]. Briefly, prospective cohort
studies were eligible for participation if they had enrolled
at least 100 HIV-1–infected patients aged 16 years orpyright © Lippincott Williams & Wilkins. Unauthormore who had not previously received antiretroviral
treatment, started ART with a combination of at least
three antiretroviral drugs after 1996, and been followed
for a median duration of at least 1 year after ART
initiation. The database was updated in 2007 to
additionally include patients who had started ART up
until 31 December 2005 with follow-up until 1 July
2006. All cohorts have been approved by their local ethics
committees or institutional review boards, use standar-
dized methods of data collection, and schedule follow-up
visits at least once every 6 months.
The cohorts in the dataset for this analysis are French
Hospital Database on HIV (FHDH) ANRS CO4 [27]
and the Aquitaine Cohort ANRS CO3 (France) [28], the
AIDS Therapy Evaluation project Netherlands
(ATHENA) [29], Italian Cohort of Antiretroviral-Naive
Patients (ICONA) [30], Swiss HIV Cohort Study
(SHCS) [31], Frankfurt HIV Cohort [32] and Ko¨ln/
Bonn Cohort (Germany) [33], the EuroSIDA study (20
countries in Europe and Argentina) [34], the Collabor-
ations in HIVOutcomes Research US (CHORUS) [35],
the University of Alabama at Birmingham 1917 Clinic
Cohort [36] and the Veterans Aging Cohort Study
(VACS) (USA) [37], the Royal Free Hospital Cohort
(United Kingdom) [38], the British Columbia Centre for
Excellence in HIV/AIDS [39] and the South Alberta
Clinic (Canada) [40], and PISCIS, Catalonia and Balearic
Islands (Spain) [41].
Data collection
Patient selection and data extraction were performed at
the data centres of the participating cohorts. Anonymized
data on a predefined set of demographic, laboratory, and
clinical variables were pooled and analysed centrally.
Cohort data managers from EuroSIDA were asked to
provide a unique study identification for each record as
EuroSIDA patients may also be members of other
cohort studies.
Statistical analyses
Analyses were restricted to HIV-1-positive patients aged
16 years or older, who first started antiretroviral therapy in
the period 1 January 2000 to 31 December 2005 and had
at least 6 months of potential follow-up before the
cohort-specific database close date. Because of the focus
on more recent ART regimens, study inclusion criteria
required initiation of efavirenz (EFV), nevirapine (NVP),
lopinavir/ritonavir (LPV/r), nelfinavir (NFV), or abaca-
vir (ABC) as ‘third drugs’. We evaluated short-term
(24-week) virologic failure (HIV RNA >500 copies/ml)
and longer-term clinical outcomes (incident AIDS-
defining event, death from any cause, and a composite
measure of these two outcomes) by third drug, in patients
who were taking zidovudine and lamivudine (ZDV and
3TC) as the nucleoside reverse transcriptase inhibitor
(NRTI) backbone. This approach was taken to focus on
differences in virologic failure and clinical outcomesized reproduction of this article is prohibited.
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NRTI pair, such that potential differences in prescribing
patterns for NRTI backbones across third drugs was not a
factor. ZDVand 3TCwere chosen as theNRTI backbone
as this combination represented the most commonly
prescribed NRTI pair (68% of regimens). All centres used
the 1993 US Centers for Disease Control and Prevention
criteria and guidelines for the definitive or presumptive
diagnosis of AIDS-defining events [42]. Only new AIDS
diagnosis, defined as the first occurrence of each AIDS-
defining condition was considered to be an incident
event; recurrences of conditions were not considered.
Change in regimen at 6 months after initiating ARTwas a
secondary outcome.
To evaluate short-term virologic failure, logistic
regression models were used to estimate crude and
adjusted odds ratios (ORs) of detectable 24-week plasma
HIV-1 RNA, that is more than 500 copies/ml, among
patients with an available measurement at that time (3-
month window). For this analysis, patients who died prior
to 24 weeks and those with missing 24-week plasma HIV-
1 RNA values were excluded. Logistic regression models
were also used to estimate the crude and adjusted OR of
not being on the initial regimen at 24 weeks; 24-week
regimen change was evaluated as a secondary outcome
measure. Sensitivity analyses were conducted evaluating
24-week virologic failure and initial ART regimen
change for all patients, including those with missing
24-week measurements. For these analyses, patients with
missing 24-week plasma HIV RNA measures (3
months), including those who died, were considered
treatment failures (’missing equals failure’).
To evaluate clinical outcomes, we measured time from
the date of initiating ART to earlier of the date that
clinical endpoints occurred and the date of censoring
(end of follow-up). In patients free of events, follow-up
was censored on the date of the most recent visit plus
half the usual visit interval (usually 3 months) for AIDS
and the combined endpoint (incident AIDS event or
death from any cause). For mortality, the censoring date
was extended to the date the patient was last known to
be alive in cohorts that could assert complete vital
registration; otherwise, as above. Because the pro-
portion of patients remaining on their initial regimen
decreases over time, effects of initial regimen become
increasingly diluted by regimen changes with increasing
time since initiation of ART. Follow-up was therefore
censored at 2 years after starting ARTor at the cohort-
specific close of database date, if either of these occurred
sooner. Additional analyses, removing the 2-year
censoring, were conducted to evaluate longer-term
differences in clinical events according to initial ART
regimen.
Weibull proportional hazards regressionmodels were used
to model the association of initial treatment regimen andopyright © Lippincott Williams & Wilkins. Unauthother prognostic factors with disease progression as
measured by clinical outcome measures. We estimated
crude and adjusted hazard ratios comparing other third
drugs with EFV when taken in combination with ZDV
and 3TC. Analyses followed an ‘intent to continue initial
therapy’ principle, in that eligible participants were
analysed according to initial regimen, regardless of
whether they later discontinued or modified their
therapeutic regimen.
All multivariable models were adjusted for age at
initiation of therapy (16–29, 30–39, 40–49, and >50
years), sex, transmission risk group [injection drug user
(IDU), non-IDU], clinical stage (A/B, C), baseline CD4
cell count (<25, 25–49, 50–99, 100–199, 200–349, and
350 cells/ml), baseline plasma HIV-1 RNA (<1000,
1000–9999 10 000–99 999, and 100 000 copies/ml),
year of starting ARTand cohort. Sensitivity analyses were
restricted to patients who started ARTwith a CD4 cell
count 200 cells/ml or less and to those whose reported
transmission risk group was non-IDU.
AIDS-free survival up to 2 years after initiation of therapy
by third drug was plotted using the estimated probability
of a survival free of an incident AIDS-defining event or
death from the adjustedWeibull model with covariates set
at their average value across the population of patients and
for the cohort with median survival.Results
Overall, 13 546 patients in the ART-CC initiated ART
with the third drugs of interest (EFV, NVP, LPV/r, NFV,
ABC) paired with ZDV and 3TC during the study
period. Among study participants, 69% were men, 13%
reported a history of IDU, and 20% had CDC clinical
stage C disease (Table 1). Overall, the median age
(interquartile range) was 38 years (31–45) and the
median CD4 cell count and plasma log10 HIV RNA
levels were 218 cells/ml (104–329) and 4.9 (4.4–5.3),
respectively, at the time of ART initiation. During the
study period, EFV was the most commonly prescribed
third drug (28%), followed by LPV/r (21%), ABC
(19%), NFV (16%), and NVP (16%). Temporal trends in
prescribing patterns measured as the proportion of
overall ART prescriptions in a given year represented by
each antiretroviral drug indicated increased use of
LPV/r and decreased use of all other third drugs over
the course of the observation period (Fig. 1). Compared
with other third drugs, LPV/r was more commonly
prescribed to patients with lower CD4 cell counts
(median 150 cells/ml) and higher plasma HIV RNA
levels (5.1 log10 copies/ml), whereas the opposite was
observed for ABC (median 251 cells/ml and 4.7
log10 copies/ml) and NVP (median 260 cells/ml and
4.7 log10 copies/ml) (Table 1).orized reproduction of this article is prohibited.
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Table 1. Patient characteristics of 13546 antiretroviral naı¨ve HIV-infected patients in the Antiretroviral Therapy Cohort Collaboration initiating
ART with zidovudine and lamivudine stratified by third drug, 2000–2005.
Overall EFV NVP LPV/r NFV ABC
Frequency third drug [N (row %)] 13546 (100) 3788 (28) 2151 (16) 2875 (21) 2217 (16) 2515 (19)
Characteristic by third drug
N (column %)
Male 9368 (69) 2967 (78) 1306 (61) 2088 (73) 1229 (55) 1778 (71)
IDU 1740 (13) 492 (13) 261 (12) 232 (8) 321 (14) 434 (17)
Clinical CDC stage C 2674 (20) 848 (22) 255 (12) 766 (27) 443 (20) 362 (14)
Median (IQR)
Age (years) 38 (31–45) 39 (33–47) 36 (30–43) 38 (32–46) 36 (29–44) 38 (32–46)
CD4 cell count (cells/ml) 218 (104 –329) 207 (94–320) 260 (171–366) 150 (55–264) 214 (92–351) 251 (163–354)
HIV RNA (log copies/ml) 4.9 (4.4–5.3) 4.9 (4.5–5.4) 4.7 (4.2–5.1) 5.1 (4.7–5.5) 4.8 (4.2–5.3) 4.7 (4.2–5.1)
3TC, lamivudine; ABC, abacavir; EFV, efavirenz; IQR, interquartile range; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; NVP, nevirapine; ZDV,
zidovudine.In multivariable logistic regression analyses among
patients who had 24-week plasma HIV RNA measures
(n¼ 11 194, 83%), detectable 24-week plasma HIVRNA
(>500 copies/ml) was more common with all other third
drugs than with EFV (Table 2). Findings were most
pronounced for NFV (adjusted OR¼ 3.20, 95%
CI¼ 2.74–3.74), whereas patients treated with NVP
(1.87, 95% CI¼ 1.58–2.22) and ABC (2.13, 95%
CI¼ 1.82–2.50) had roughly twice the odds of short-
term virologic failure. There was a modest increase in the
odds of 24-week virologic failure for LPV/r (adjusted
OR¼ 1.32, 95% CI¼ 1.12–1.57). Among those with
available 24-week data (n¼ 11 338, 84% of cohort),
patients receiving NVP (adjusted OR¼ 1.30, 95%
CI¼ 1.13–1.51) and NFV (1.39, 95% CI¼ 1.20–1.60)
were less likely to be treated with their initial regimen at
24 weeks than those receiving EFV (Table 2).pyright © Lippincott Williams & Wilkins. Unauthor
Fig. 1. Temporal trends in antiretroviral prescribing patterns
among 13546 antiretroviral naı¨ve HIV-infected patients in
the Antiretroviral Therapy Cohort Collaboration initiating
antiretroviral therapy with ZDV/3TC and stratified by third
drug, 2000–2005. ABC, abacavir; EFV, efavirenz; LPV/r,
lopinavir/ritonavir; NFV, nelfinavir; NVP, nevirapine. Shaded
bars represent the proportion of Antiretroviral Therapy Cohort
Collaboration (ART-CC) patients initiating HAART with each
of the listed third drugs during each of the calendar years from
2000 to 2005.In general, sensitivity analyses including all patients
(n¼ 13 546) and utilizing a ‘missing equals failure’
approach gave similar results to those observed in primary
analyses, but with ORs that were attenuated towards one
(Table 3). In these analyses, the odds of virologic failure
were similar for LPV/r relative to EFV (adjusted
OR¼ 1.03, 95% CI¼ 0.91–1.16). This is in contrast
to the primary analyses in which the odds of 24-week
virologic failure were higher with LPV/r compared with
that in EFV. Sensitivity analyses of 24-week change of
initial ART regimen yielded similar results to primary
analyses, and parameter estimates were of comparable
magnitude (Table 3).
In Weibull proportional hazards analysis of clinical
outcomes, rates of incident AIDS events (adjusted hazard
ratio¼ 1.28, 95% CI¼ 1.02–1.60), death (1.54, 95%
CI¼ 1.09–2.19), and combined clinical outcome (1.27,
95% CI¼ 1.04–1.56) appeared higher for NVP than for
EFV (Table 4). Because baseline CD4 cell counts tended
to be higher for patients initiating NVP (median baseline
CD4 cell count 260 cells/ml) than those starting EFV
(median 207 cells/ml), adjusted hazard ratios for this
comparison were markedly greater than crude hazard
ratios. In contrast, for the comparison of LPV/r (median
baseline CD4 cell count 150 cells/ml) with EFV adjusted
hazards were attenuated towards one after controlling for
patient characteristics at baseline. In adjusted analyses,
there was little evidence that rates of clinical events in
patients on LPV/r differed from those in patients
receiving EFV (AIDS-event adjusted hazard ratio¼ 1.14,
1.14, 95% CI¼ 0.93–1.39, death 1.12, 95% CI¼ 0.80–
1.57, combined outcome measure 1.13, 95% CI¼ 0.94–
1.36) (Table 4). Figure 2 shows that by 2 years after
starting ART, there was an estimated difference of about
2% in the cumulative probability of AIDS-free survival,
between patients initiating ART on NFV and those
initiating NVP.
Relative to EFV, hazards of AIDS events (adjusted hazard
ratio¼ 0.98, 95% CI¼ 0.79–1.21), death (0.89, 95%
CI¼ 0.63–1.28), and the combined clinical endpointized reproduction of this article is prohibited.
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Table 2. Short-term (24-week) regimen durability and virologic failure among 11338 antiretroviral naı¨ve HIV-infected patients in the
Antiretroviral Therapy Cohort Collaboration (plasma HIV RNA >500copies/ml) initiating ART with zidovudine and lamivudine stratified by
third drug, 2000–2005.
Odds ratio (95% CI)
No longer on initial regimen
at 24 weeks
24-week virologic failure ART-CC
(plasma HIV RNA >500 copies/ml)
Third drug Observed N (%) Crude Adjusteda Observed N (%) Crude Adjusteda
EFV 3258 679 (21) 1 1 3087 383 (12) 1 1
NVP 1759 448 (25) 1.30 (1.13–1.49) 1.30 (1.13–1.51) 1776 348 (20) 1.72 (1.47–2.02) 1.87 (1.58–2.22)
LPV/r 2518 622 (25) 1.25 (1.10–1.41) 1.04 (0.91–1.19) 2457 365 (15) 1.23 (1.06–1.44) 1.32 (1.12–1.57)
NFV 1715 490 (29) 1.52 (1.33–1.74) 1.39 (1.20–1.60) 1829 593 (32) 3.39 (2.93–3.92) 3.20 (2.74–3.74)
ABC 2088 432 (21) 0.99 (0.87–1.13) 0.94 (0.81–1.08) 2045 486 (24) 2.20 (1.90–2.55) 2.13 (1.82–2.50)
ABC, abacavir; ART-CC, Antiretroviral Therapy Cohort Collaboration; CI, confidence interval; EFV, efavirenz; LPV/r, lopinavir/ritonavir; NFV,
nelfinavir; NVP, nevirapine.
aMultivariable logistic regressionmodels adjusted for age, sex, injection drug user (IDU), entry CD4, entry HIV RNA, year starting ART, and cohort.(0.92, 95% CI¼ 0.76–1.11) were slightly lower for NFV
(Table 4). In adjusted analyses, hazards of death (adjusted
hazard ratio¼ 1.41, 95% CI¼ 1.01–1.99) and the
combined clinical endpoint (1.22, 95% CI¼ 1.00–
1.48) appeared higher for ABC than for EFV. Such
differences were not apparent in unadjusted analyses, in
part because the median baseline CD4 cell count was
higher for patients on ABC (median 251 cells/ml) than for
those on EFV (median 207 cells/ml).
In general, sensitivity analyses of the combined clinical
outcome measure (incident AIDS event or death)
restricted to patients with baseline CD4 cell counts
200 cells/ml or less when initiating ART yielded
parameter estimates of similar magnitude for each third
drug relative to the primary analyses, although CIs were
wider (Table 5). However, larger shifts in hazards ratios
relative to primary analyses were observed when AIDS
events and death were modelled separately, relative to
models of the composite clinical outcome measure. On
the whole, sensitivity analyses of clinical outcomes
restricted to non-IDU patients yielded similar findings
to primary analyses (Table 6). Evaluation of longer-term
clinical events by initial ART regimen removing 2-yearopyright © Lippincott Williams & Wilkins. Unauth
Table 3. Sensitivity analysis of short-term (24-week) regimen durability a
patients in the Antiretroviral Therapy Cohort Collaboration (plasma HIV R
stratified by third drug (missing dataU failure), 2000–2005.
No longer on initial
regimen at 24 weeks
Third drug Observed N (%) Crude Adj
EFV 3788 1209 (32) 1 1
NVP 2151 840 (39) 1.37 (1.22–1.53) 1.29 (1
LPV/r 2875 979 (34) 1.10 (0.99–1.22) 1.04 (0
NFV 2217 992 (45) 1.73 (1.55–1.92) 1.54 (1
ABC 2515 859 (34) 1.11 (0.99–1.23) 1.01 (0
ABC, abacavir; ART-CC, Antiretroviral Therapy Cohort Collaboration; CI,
nelfinavir; NVP, nevirapine.
aMultivariable logistic regressionmodels adjusted for age, sex, injection drugcensoring yielded similar results to primary analyses,
although, as expected, hazard ratios were attenuated
towards one (Table 7).Discussion
Among antiretroviral-naı¨ve patients initiating ART in
clinical practice settings, short-term (24-week) virologic
failure was more common for all third drugs evaluated
(NVP, LPV/r, NFV, and ABC) relative to EFV when
given in combination with ZDV and 3TC. However,
compared with EFV, estimated rates of AIDS and death
appeared higher only with NVP and ABC. For LPV/r
and NFV, we found little evidence that rates of AIDS and
death differed from those on EFV. Taken together, these
findings suggest that, between ART regimen, differences
in short-term virologic failure do not necessarily translate
to differences in clinical outcomes.
Although suppression of plasma HIV RNA is an
important goal of treatment to avoid the emergence of
viral resistance among other reasons, the ultimate aim oforized reproduction of this article is prohibited.
nd virologic failure among 13546 antiretroviral naı¨ve HIV-infected
NA >500copies/ml) initiating ART with zidovudine and lamivudine
Odds ratio (95% CI)
24-week virologic failure ART-CC
(plasma HIV RNA >500copies/ml)
usteda N (%) Crude Adjusteda
1084 (29) 1 1
.14–1.45) 723 (34) 1.26 (1.13–1.42) 1.44 (1.27–1.63)
.92–1.16) 783 (27) 0.93 (0.84–1.04) 1.03 (0.91–1.16)
.37–1.72) 981 (44) 1.98 (1.77–2.21) 1.98 (1.76–2.22)
.90–1.14) 956 (38) 1.53 (1.37–1.70) 1.53 (1.36–1.72)
confidence interval; EFV, efavirenz; LPV/r, lopinavir/ritonavir; NFV,
user (IDU), entry CD4, entry HIV RNA, year starting ART, and cohort.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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VF and clinical events by ART regimen (ART-CC) 2487
Fig. 2. Estimated AIDS free survival among 13546 antire-
troviral naı¨ve HIV-infected patients in the Antiretroviral
Therapy Cohort Collaboration initiating antiretroviral
therapy with ZDV/3TC stratified by third drug, 2000–
2005. Survival curves shown are estimated from a Weibull
model with follow-up censored at 2 years, with covariates set
at the average value across the population of patients and for
the cohort with median survival. Corresponding adjusted
hazard ratios are shown in Table 4.
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s.antiretroviral therapy is to prevent clinical progression and
death. Preferred initial ART regimens change frequently,
based on differential rates of virologic suppression
observed in clinical trials. Our study suggests that such
differences in virologic suppression between ART
regimens may not translate to differences in clinical
events among patients receiving treatment in a clinical
practice setting. This observation may relate, in part, to
the many available antiretroviral treatment options:
patients failing treatment at 24-weeks may subsequently
switch to other effective ART regimens. A recent study
recognized the association of longitudinal CD4 cell count
and plasma HIV RNA responses in contributing to long-
term clinical outcomes in patients initiating modern
ART, regardless of specific initial regimen [43].
Most previous observational studies (like RCTs) have
lacked statistical power to analyse between-regimen
differences in clinical events among patients initiating
ART [9–20]. The ART-CC makes such comparisons
possible through the collaborative efforts of multiple
observational HIV cohort studies. The current study
advances the findings of an earlier report from the ART-
CC [22], by focusing on more recent ART regimens at
the level of the third drug among patients receiving the
same NRTI backbone (ZDVand 3TC). Importantly, the
current study allowed for the evaluation of LPV/r
individually, and not grouped with other RTV-boosted
protease inhibitors (amprenavir, saquinavir, and indinavir)
as done in the earlier analysis due to the relatively small
frequency of LPV/r use during the earlier evaluation
period (1996–2002).orized reproduction of this article is prohibited.
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.In contrast with our earlier study, in which RTV-boosted
protease inhibitors were associated with increased rates of
both short-term virologic failure and clinical outcomes
compared with EFV [22], LPV/r was associated only with
24-week virologic failure in the current study. The AIDS
Clinical Trial Group (ACTG) 5142 study found a higher
frequency of virologic failure among ARV-naı¨ve patients
treated with two NRTIs and LPV/r compared with those
treated with two NRTIs and EFV [44]. Although EFV
outperformed LPV/r in achieving plasma HIV RNA
levels of less than 50 copies/ml and showed a trend for
superiority at less than 200 copies/ml, increases in CD4
cell counts were greater for patients receiving LPV/r than
for those receiving EFV in that randomized clinical trial.
In the current study, similar 24-week CD4 responses were
observed for patients treated with LPV/r and EFV
(median CD4 cell count increase 110 vs. 100 cells/ml,
respectively). These similar CD4 responses among ART-
CC patients treated with LPV/r and EFV may have
contributed to comparable hazards of clinical outcomes,
despite a higher frequency of 24-week virologic failure in
patients treated with LPV/r.
Another possible explanation for the apparent lack of
difference in clinical endpoints between EFV and LPV/r
may relate to varying resistance patterns emerging upon
treatment failure between different initial ARTregimens.
Recently, it was shown that patients failing a first-line
nonnucleoside reverse transcriptase inhibitor (NNRTI)
containing regimen harboured viruses with higher
numbers of IAS-USA drug resistance mutations and
resistance to more antiretroviral drug classes when
compared with patients initiating therapy with ritona-
vir-boosted protease inhibitor containing regimens [45].
Thus, EFV-based regimens, although more virologically
effective as shown in this study, may result in more HIV
resistance upon failure making it more difficult to
generate potent successive ART regimens. In contrast, it
might be easier to find effective salvage regimens for
patients failing an initial boosted protease inhibitor
regimen due to the lower number of drug resistance
mutations observed. Furthermore, another study found
the emergence of resistance to NNRTIs was associated
with a greater risk of subsequent death than was the
emergence of protease inhibitor resistance [46].
This updated analysis of the ART-CC found higher odds
of 24-week virologic failure and hazards of clinical
endpoints with NVP compared with EFV in analyses
adjusted for covariates (Table 4). The findings regarding
virologic failure are in contrast to the 2NN clinical trial
[47], but consistent with other observational studies
comparing these NNRTIs [18–20]. Although we are not
able to determine the reasons for the observed inferior
virologic and clinical outcomes associated with NVP use
in the current study, it is possible that EFVoutperformed
NVP in a clinical practice setting. It is also possible that
unmeasured confounders associated with NVP selectionized reproduction of this article is prohibited.
CVF and clinical events by ART regimen (ART-CC) 2489in clinical practice, confounding by indication, con-
tributed to the inferior outcomes for NVP in the current
study. Notably, shifts in parameter estimates for both NVP
(increased) and LPV/r (decreased) for clinical outcome
measures were observed between unadjusted and adjusted
analyses attributable to differential patient profiles (e.g.,
baseline CD4 cell count and plasma HIV viral load)
among patients stratified by third drug receipt (Table 1).
The impact of confounding by indication in the selection
of third drugs was more apparent in the evaluation of
clinical outcomes than observed in analyses of short-term
virologic failure; more marked shifts in parameter
estimates between crude and adjusted analyses were
observed for the clinical outcomes models (Tables 2
and 4). Prior studies have shown the importance of
baseline CD4 cell counts at the time of ART initiation on
subsequent clinical events [24,48]. Taking into account
the drastically different median CD4 cell counts among
patients initiating ARTobserved in this study (e.g., LPV/r
150 cells/ml, NVP 260 cells/ml, and ABC 251 cells/ml), it
would be expected that multivariable models controlling
for these differences would lead to shifts in estimates
observed for crude analyses, as was seen. Although the
impact of confounding by indication is observed across
analyses in this study, it is notable that sensitivity analyses
of adjusted models largely yielded consistent findings to
those observed in primary analyses.
The findings of our study must be interpreted with regard
to the study limitations. The potential for confounding is
inherent to all observational studies. The impact of
confounding by indication is demonstrated and discussed
in this study, but it is possible that other unmeasured
confounders not included in adjusted statistical models
may have contributed to observed study findings. As with
prior studies of the ART-CC, we have adjusted for factors
associated with clinical events (e.g., baseline CD4 cell
count), but cannot rule out the possibility of unmeasured
confounding. For example, it is possible that a provider’s
selection of initial ART regimen was influenced by their
expectations of a patient’s adherence to their antiretroviral
medications. Such prescribing bias may represent
unmeasured confounding that contributed to the
between-regimen differences in outcomes observed in
this study. Furthermore, between-provider differences
(e.g., experience) may also have contributed to differ-
ential outcomes. Finally, although the ART-CC has broad
geographic representation from Europe and North
America, findings of this study may not apply to other
geographic settings.
In summary, among patients initiating ART from 2000 to
2005 in clinical practice settings with a ZDV and 3TC
backbone, those receiving third drugs other than EFV
(NVP, LPV/r, NFV, and ABC) were more likely to
experience short-term (24-week) virologic failure.
However, such differences were not as prominent inopyright © Lippincott Williams & Wilkins. Unauththe evaluation of clinical events, which were more
common (relative to EFV) in patients receiving NVP and
ABC as the third drug of their initial ART regimen, but
with little evidence of such differences for those receiving
NFV and LPV/r. This study clearly demonstrates the
impact of confounding by indication: such confounding,
as well as the potential for unmeasured confounding
should be taken into account when conducting,
evaluating, and reviewing studies utilizing this method-
ology [6,49]. Because of the limited available evidence
from randomized trials on the impact of initial ART
regimens on rates of clinical events, findings from well
designed observational cohort studies may serve a
complementary role to findings from clinical trials in
informing clinical practice.Acknowledgements
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